Latest Administration News

InhaleRx has boosted its funding facility by $12.6 million to accelerate clinical trials of SRX-25, a novel oral treatment for Treatment-Resistant Depression. This brings total available capital to $52.3 million, positioning the company for pivotal Phase III studies.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

Island Pharmaceuticals has submitted critical responses to the FDA, advancing the development of its antiviral Galidesivir under the Animal Rule pathway. The company awaits FDA feedback expected by early January 2026, setting the stage for upcoming Marburg virus studies.

Argenica Therapeutics has demonstrated that its lead drug candidate ARG-007 does not interfere with the clot-busting agent tenecteplase, fulfilling a critical FDA requirement and advancing its stroke therapy development.

Pacific Edge appoints Simon Flood as chairman designate, aiming to leverage his global investment expertise to navigate Medicare reimbursement challenges for its bladder cancer diagnostic tests in the US.

Avecho Biotechnology has received patent allowances in the US and Europe for its proprietary CBD soft-gel formulation, reinforcing its intellectual property ahead of pivotal Phase III insomnia trial results expected in mid-2026.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Pursuit Minerals has satisfied all acquisition conditions for the Sascha Marcelina Gold Project in Argentina and is advancing exploration with a focus on high-potential drill targets. Concurrently, the company progresses its Rio Grande Sur Lithium Project feasibility study, positioning itself for dual-commodity growth.

Jameson Resources has locked in a $3 million capital raise from strategic investor King George Investments to advance its Crown Mountain coal project in British Columbia. The placement, priced at a 16.7% discount, underscores growing confidence in the project’s regulatory progress and market potential.

VanEck Investments Limited has released an updated Product Disclosure Statement detailing its suite of Australian fixed income ETFs, outlining fund strategies, risk factors, and fee structures.

VanEck Investments Limited has released an updated Product Disclosure Statement for seven Australian dollar-denominated bond ETFs listed on the ASX, detailing investment strategies, risks, and fees.

VanEck Investments Limited has released a comprehensive Product Disclosure Statement for its suite of seven Australian bond ETFs, detailing investment strategies, risks, fees, and operational frameworks under the ASX AQUA Rules.